National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to ...
Precigen on Tuesday said a green light would make PRGN-2012 the only FDA-approved therapeutic for the treatment of adults with the disorder, which is a lifelong neoplastic disease of the upper and ...
Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio” or the "Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback